SG11202010906XA - R-fadrozole for use in the treatment of aldostonerism - Google Patents
R-fadrozole for use in the treatment of aldostonerismInfo
- Publication number
- SG11202010906XA SG11202010906XA SG11202010906XA SG11202010906XA SG11202010906XA SG 11202010906X A SG11202010906X A SG 11202010906XA SG 11202010906X A SG11202010906X A SG 11202010906XA SG 11202010906X A SG11202010906X A SG 11202010906XA SG 11202010906X A SG11202010906X A SG 11202010906XA
- Authority
- SG
- Singapore
- Prior art keywords
- aldostonerism
- fadrozole
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862666412P | 2018-05-03 | 2018-05-03 | |
| EP18176345 | 2018-06-06 | ||
| PCT/EP2019/061283 WO2019211394A1 (en) | 2018-05-03 | 2019-05-02 | R-fadrozole for use in the treatment of aldostonerism |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202010906XA true SG11202010906XA (en) | 2020-12-30 |
Family
ID=66334511
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202010906XA SG11202010906XA (en) | 2018-05-03 | 2019-05-02 | R-fadrozole for use in the treatment of aldostonerism |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20210169861A1 (en) |
| EP (1) | EP3787623A1 (en) |
| JP (1) | JP7470050B2 (en) |
| KR (1) | KR20210005684A (en) |
| CN (1) | CN112055590A (en) |
| AU (1) | AU2019262310A1 (en) |
| BR (1) | BR112020022173A2 (en) |
| CA (1) | CA3097281A1 (en) |
| CL (1) | CL2020002803A1 (en) |
| MX (1) | MX2020011471A (en) |
| PH (1) | PH12020551654A1 (en) |
| SG (1) | SG11202010906XA (en) |
| WO (1) | WO2019211394A1 (en) |
| ZA (1) | ZA202006886B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024079324A1 (en) | 2022-10-14 | 2024-04-18 | Damian Pharma Ag | Once daily aldosterone synthase inhibitor (r)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[l,5-a]pyridine |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4889861A (en) | 1982-12-21 | 1989-12-26 | Ciba-Geigy Corp. | Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors |
| US4617307A (en) | 1984-06-20 | 1986-10-14 | Ciba-Geigy Corporation | Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors |
| US4728645A (en) | 1982-12-21 | 1988-03-01 | Ciba-Geigy Corporation | Substituted imidazo[1,5-A]pyridine derivatives and other substituted bicyclic derivatives, useful as aromatase inhibitors |
| US5057521A (en) | 1988-10-26 | 1991-10-15 | Ciba-Geigy Corporation | Use of bicyclic imidazole compounds for the treatment of hyperaldosteronism |
| MTP1076B (en) | 1990-01-12 | 1991-09-30 | Ciba Geigy Ag | Hemihydrate |
| NZ534086A (en) * | 2000-04-12 | 2006-08-31 | Novartis Ag | Use of an aldosterone synthase inhibitor in combination with an angiotensin I receptor antagonist or an angiotensin I receptor antagonist plus a diuretic to treat various conditions |
| IL152081A0 (en) | 2000-04-12 | 2003-05-29 | Novartis Ag | Novel medical use of aldosterone synthase inhibitors alone or in combination with at1-receptor antagonists |
| WO2005099695A1 (en) * | 2004-04-19 | 2005-10-27 | Novartis Ag | Drug delivery systems for the prevention and treatment of vascular diseases |
| EP1886695A1 (en) * | 2006-06-27 | 2008-02-13 | Speedel Experimenta AG | Pharmaceutical combination of an aldosterone synthase inhibitor and a glucocorticoid receptor antagonist or a cortisol synthesis inhibitor or a corticotropin releasing factor antagonist |
| WO2018078049A1 (en) | 2016-10-27 | 2018-05-03 | Damian Pharma Ag | Aldosterone synthase inhibitor |
-
2019
- 2019-05-02 WO PCT/EP2019/061283 patent/WO2019211394A1/en active Application Filing
- 2019-05-02 CN CN201980029203.4A patent/CN112055590A/en active Pending
- 2019-05-02 BR BR112020022173-2A patent/BR112020022173A2/en unknown
- 2019-05-02 KR KR1020207033916A patent/KR20210005684A/en unknown
- 2019-05-02 EP EP19720657.6A patent/EP3787623A1/en active Pending
- 2019-05-02 CA CA3097281A patent/CA3097281A1/en active Pending
- 2019-05-02 SG SG11202010906XA patent/SG11202010906XA/en unknown
- 2019-05-02 US US17/052,359 patent/US20210169861A1/en active Pending
- 2019-05-02 JP JP2020560487A patent/JP7470050B2/en active Active
- 2019-05-02 MX MX2020011471A patent/MX2020011471A/en unknown
- 2019-05-02 AU AU2019262310A patent/AU2019262310A1/en active Pending
-
2020
- 2020-10-06 PH PH12020551654A patent/PH12020551654A1/en unknown
- 2020-10-28 CL CL2020002803A patent/CL2020002803A1/en unknown
- 2020-11-04 ZA ZA2020/06886A patent/ZA202006886B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3097281A1 (en) | 2019-11-07 |
| CN112055590A (en) | 2020-12-08 |
| AU2019262310A1 (en) | 2020-11-12 |
| EP3787623A1 (en) | 2021-03-10 |
| PH12020551654A1 (en) | 2021-07-26 |
| BR112020022173A2 (en) | 2021-02-02 |
| KR20210005684A (en) | 2021-01-14 |
| JP2021522289A (en) | 2021-08-30 |
| MX2020011471A (en) | 2020-12-07 |
| ZA202006886B (en) | 2022-07-27 |
| CL2020002803A1 (en) | 2021-03-12 |
| US20210169861A1 (en) | 2021-06-10 |
| JP7470050B2 (en) | 2024-04-17 |
| WO2019211394A1 (en) | 2019-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL268210A (en) | Use of gaboxadol in the treatment of tinnitus | |
| GB201820450D0 (en) | Compound and its use for the treatment of alpha1-antitryspin deficiency | |
| PL3277280T3 (en) | Isomyosmine for use in the treatment of autoimmune diseases | |
| GB201813876D0 (en) | Treatment | |
| IL246855A0 (en) | Agents for use in the treatment of retinal inflammation | |
| GB201800546D0 (en) | Treatment | |
| HK1256164A1 (en) | Agents for use in the treatment of glioma | |
| IL277805A (en) | Use of gaboxadol in the treatment of substance use disorders | |
| EP3440052C0 (en) | Compounds for use in the treatment of cancer | |
| IL269121A (en) | Usl-311 for use in the treatment of cancer | |
| IL289371A (en) | Methylthioninium for use in the treatment of synaptopathies | |
| ZA202006886B (en) | R-fadrozole for use in the treatment of aldostonerism | |
| IL286533A (en) | Compounds for use in the treatment of adcy5-related dyskinesia | |
| IL273863A (en) | Device for use in the treatment of hemorrhoids | |
| EP3870180C0 (en) | Combination comprising sildenafil for use in the treatment of osteoarthritis | |
| ZA201806894B (en) | (+)-azasetron for use in the treatment of ear disorders | |
| EP3648789C0 (en) | Mtmr2-s polypeptide for use in the treatment of myopathies | |
| GB2581876B (en) | Compositions for use in the treatment of endometrial disorder | |
| SI3548006T1 (en) | Composition for use in the treatment of intestinal alterations | |
| SG11202100269VA (en) | Compounds for use in the treatment of fascioliasis | |
| ZA202001435B (en) | Abx196 for use in the treatment of bladder cancer | |
| IL268265B (en) | 3-beta-hydroxy-5-alpha-pregnan-20-one for use in medical treatment | |
| GB201820455D0 (en) | Compounds and their use for the treatment of alpha1-antitryspin deficiency | |
| GB201820452D0 (en) | Compounds and their use for the treatment of alpha1-antitryspin deficiency | |
| GB201820451D0 (en) | Compounds and their use for the treatment of alpha1-antitryspin deficiency |